Publication Date
| In 2025 | 1 |
| Since 2024 | 2 |
| Since 2021 (last 5 years) | 5 |
| Since 2016 (last 10 years) | 11 |
| Since 2006 (last 20 years) | 28 |
Descriptor
| Drug Therapy | 31 |
| Children | 19 |
| Autism | 17 |
| Behavior Problems | 17 |
| Symptoms (Individual… | 16 |
| Pervasive Developmental… | 15 |
| Check Lists | 14 |
| Outcomes of Treatment | 13 |
| Hyperactivity | 8 |
| Adolescents | 7 |
| Adults | 7 |
| More ▼ | |
Source
Author
Publication Type
| Journal Articles | 31 |
| Reports - Research | 27 |
| Reports - Evaluative | 3 |
| Information Analyses | 1 |
Education Level
Audience
Location
| North Carolina | 2 |
| Australia | 1 |
| California (Los Angeles) | 1 |
| Canada | 1 |
| Connecticut (New Haven) | 1 |
| Illinois (Chicago) | 1 |
| Massachusetts (Boston) | 1 |
| Michigan | 1 |
| Norway | 1 |
| Thailand | 1 |
| United Kingdom | 1 |
| More ▼ | |
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Peer reviewed
Direct linkTrine Lise Bakken; Jane Margrete Askeland Hellerud; Arvid Nikolai Kildahl; Ann Magritt Solheim-Inderberg; Oddbjørn Hove; Sissel Berge Helverschou – Journal of Autism and Developmental Disorders, 2025
Autistic people with intellectual disabilities appear to be at increased risk of schizophrenia. While current recommendations emphasize adapting interventions used for people with schizophrenia in general, few studies to date have investigated treatment of co-occurring schizophrenia in this specific population. To explore what interventions are…
Descriptors: Autism Spectrum Disorders, Intellectual Disability, Schizophrenia, Comorbidity
Lloyd, Blair P.; Weaver, Emily S.; Torelli, Jessica N.; Pollack, Marney S.; Fareed, Sunya A.; Maxwell-Horn, Angela C. – American Journal on Intellectual and Developmental Disabilities, 2021
The purpose of the current study was to explore the scientific utility of two behavior analytic assessments (i.e., progressive ratio and demand assessments) for psychotropic medication evaluation. For a sample of 23 children with disabilities who were prescribed medication, we conducted a series of generalizability and optimization studies to…
Descriptors: Disabilities, Children, Drug Therapy, Behavior Problems
Shurtz, Logan; Schwartz, Chloe; DiStefano, Charlotte; McPartland, James C.; Levin, April R.; Dawson, Geraldine; Kleinhans, Natalia M.; Faja, Susan; Webb, Sara J.; Shic, Frederick; Naples, Adam J.; Seow, Helen; Bernier, Raphael A.; Chawarska, Katarzyna; Sugar, Catherine A.; Dziura, James; Senturk, Damla; Santhosh, Megha; Jeste, Shafali S. – Autism: The International Journal of Research and Practice, 2023
Children with autism spectrum disorder are prescribed various medications to address behavior and mood. In clinical trials, individuals taking concomitant psychotropic medications often are excluded to maintain homogeneity and prevent contamination of clinical endpoints. However, this choice may compromise the representativeness of the sample. In…
Descriptors: Autism Spectrum Disorders, Drug Therapy, Incidence, Child Behavior
Latent Class Analysis Identifies Distinctive Behavioral Subtypes in Children with Fragile X Syndrome
Walter E. Kaufmann; Melissa Raspa; Carla M. Bann; Julia M. Gable; Holly K. Harris; Dejan B. Budimirovic; Reymundo Lozano – Journal of Autism and Developmental Disorders, 2024
Fragile X syndrome (FXS) is characterized by variable neurobehavioral abnormalities, which leads to difficulties in developing and evaluating treatments and in determining accurate prognosis. We employed a pediatric cross-sectional sample (1,072 males, 338 females) from FORWARD, a clinic-based natural history study, to identify behavioral subtypes…
Descriptors: Symptoms (Individual Disorders), Children, Genetic Disorders, Intellectual Disability
Chez, Michael; Kile, Shawn; Lepage, Christopher; Parise, Carol; Benabides, Bobbie; Hankins, Andrea – Journal of Autism and Developmental Disorders, 2020
Prior studies have demonstrated successful irritability treatment using dopaminergic antagonists in autistic patients. The purpose of this pilot study was to assess the effect of dextromethorphan/quinidine (DM/Q) in autistic adults (18-60 years of age). This was a randomized, blinded, crossover, study of 14 patients randomized to DM/Q or a placebo…
Descriptors: Outcomes of Treatment, Randomized Controlled Trials, Pilot Projects, Drug Therapy
Blickwedel, Jessica; Vickerstaff, Victoria; Walker, Matthew; Hassiotis, Angela – Journal of Intellectual & Developmental Disability, 2019
Background: As both epilepsy and challenging behaviour are highly prevalent in adults with intellectual disability (ID) it is important to explore any potential relationships between the two to inform patient care. The aim of the present study was to investigate the relationship between epilepsy factors and challenging behaviour in adults with ID.…
Descriptors: Behavior Problems, Epilepsy, Intellectual Disability, Seizures
Charlot, Lauren R.; Weigle, Karen L.; Holingue, Calliope B. – Journal of Mental Health Research in Intellectual Disabilities, 2021
Introduction: Individuals with Down syndrome (DS) and IDD have lower psychiatric disorders rates than other individuals with IDD, and more information is needed about possible unique mental health needs of this group. Method: De-identified intake data for individuals with IDD, 101 with DS (mean age 27) and 4,366 without DS (mean age 25) served in…
Descriptors: Down Syndrome, Intellectual Disability, Mental Health, Physical Health
Dean, Olivia M.; Gray, Kylie; Dodd, Seetal; Villagonzalo, Kristi-Ann; Brown, Ellie; Tonge, Bruce; Berk, Michael; Byrne, Linda K. – Journal of Intellectual & Developmental Disability, 2019
Background: Traditional treatment for the behavioural symptoms in autism spectrum disorder (ASD) remains unsatisfactory. There is an urgent need for new, biologically relevant therapies that target both the core and comorbid symptoms that children may experience. This article builds on research previously published by the authors. Method: We…
Descriptors: Autism, Pervasive Developmental Disorders, Intervention, Children
Lord, Catherine; McCauley, James B.; Pepa, Lauren A.; Huerta, Marisela; Pickles, Andrew – Autism: The International Journal of Research and Practice, 2020
Longitudinal data on the functioning of adults referred for possible autism as children are sparse and possibly different from datasets consisting of adult clinical referrals. A total of 123 young adults, mean age of 26, referred for neurodevelopmental disorders in early childhood were categorized into three outcome groups: autism spectrum…
Descriptors: Autism, Pervasive Developmental Disorders, Young Adults, Intelligence Quotient
Lewis, Alan S.; van Schalkwyk, Gerrit Ian; Lopez, Mayra Ortiz; Volkmar, Fred R.; Picciotto, Marina R.; Sukhodolsky, Denis G. – Journal of Autism and Developmental Disorders, 2018
Nicotinic acetylcholine receptors (nAChRs), particularly the a7 nAChR, are implicated in the pathophysiology of both autism spectrum disorder (ASD) and aggressive behavior. We explored the feasibility, tolerability, and preliminary efficacy of targeting nAChRs using transdermal nicotine to reduce aggressive symptoms in adults with ASD. Eight…
Descriptors: Aggression, Adults, Stimulants, Pervasive Developmental Disorders
Loebel, Antony; Brams, Matthew; Goldman, Robert S.; Silva, Robert; Hernandez, David; Deng, Ling; Mankoski, Raymond; Findling, Robert L. – Journal of Autism and Developmental Disorders, 2016
The aim of this study was to evaluate the short-term efficacy and safety of lurasidone in treating irritability associated with autistic disorder. In this multicenter trial, outpatients age 6-17 years who met DSM-IV-TR criteria for autistic disorder, and who demonstrated irritability, agitation, and/or self-injurious behaviors were randomized to…
Descriptors: Autism, Pervasive Developmental Disorders, Drug Therapy, Psychological Patterns
Hirota, Tomoya; Veenstra-VanderWeele, Jeremy; Hollander, Eric; Kishi, Taro – Journal of Autism and Developmental Disorders, 2014
Electroencephalogram-recorded epileptiform activity is common in children with autism spectrum disorder (ASD), even without clinical seizures. A systematic literature search identified 7 randomized, placebo-controlled trials of antiepileptic drugs (AEDs) in ASD (total n = 171), including three of valproate, and one each of lamotrigine,…
Descriptors: Autism, Pervasive Developmental Disorders, Drug Therapy, Epilepsy
Fung, Lawrence K.; Libove, Robin A.; Phillips, Jennifer; Haddad, Francois; Hardan, Antonio Y. – Journal of Autism and Developmental Disorders, 2014
The objective of this study was to assess the tolerability and efficacy of pregnenolone in reducing irritability in adults with autism spectrum disorder (ASD). This was a pilot, open-label, 12-week trial that included twelve subjects with a mean age of 22.5 ± 5.8 years. Two participants dropped out of the study due to reasons unrelated to adverse…
Descriptors: Adults, Pervasive Developmental Disorders, Autism, Drug Therapy
Erickson, Craig A.; Wink, Logan K.; Early, Maureen C.; Stiegelmeyer, Elizabeth; Mathieu-Frasier, Lauren; Patrick, Vanessa; McDougle, Christopher J. – Journal of Autism and Developmental Disorders, 2014
Rationale: An excitatory/inhibitory (E:I) imbalance marked by enhanced glutamate and deficient gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of autism spectrum disorders (ASD). Objectives: We report on the first single-blind placebo lead-in trial of acamprosate, a drug with putative mechanisms restoring E:I…
Descriptors: Autism, Pervasive Developmental Disorders, Drug Therapy, Metabolism
Erickson, Craig A.; Veenstra-Vanderweele, Jeremy M.; Melmed, Raun D.; McCracken, James T.; Ginsberg, Lawrence D.; Sikich, Linmarie; Scahill, Lawrence; Cherubini, Maryann; Zarevics, Peter; Walton-Bowen, Karen; Carpenter, Randall L.; Bear, Mark F.; Wang, Paul P.; King, Bryan H. – Journal of Autism and Developmental Disorders, 2014
STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32…
Descriptors: Autism, Pervasive Developmental Disorders, Symptoms (Individual Disorders), Drug Therapy
